Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight

Comprehensive Psychiatry

Volumn 39, Issue 4, 1998, Pages 215-219

  Garavan, J ^b   Browne, S ^b   Gervin, M ^b   Lane, A ^b   Larkin, C ^b   O'Callaghan, E ^a  

^a Cluain Mhuire Family Centre   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DRUG RESPONSE; HUMAN; OUTPATIENT DEPARTMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 0031816230     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-440X(98)90063-3     Document Type: Article

References (37)

1. Davis JM. Overview: Maintenance therapy in psychiatry. I. Schizophrenia. Am J Psychiatry 1975;132:1237-1245.
2. Adams SG, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993;181:558-560.
3. Hale T. Will the new antipsychotics improve the treatment of schizophrenia? Br Med J 1993;307:749-750.
4. Hoge SK, Appelbaum PS, Lawlor T, Beck JC, Litman R, Greer A, et al. A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 1990; 47:949-956.
5. Van Putten T, Marder SR, Wirshing WC, Chabert N, Aravagiri M. Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population. Arch Gen Psychiatry 1990;47:786-787.
6. Willcox DRC, Gillan R, Hare EH. Do psychiatric outpatients take their drugs? Br Med J 1965;2:790-792.
7. Weiden P, Papkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310.
8. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 1983;13:177-183.
9. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992; 22:787-797.
10. David AS. Insight and psychosis. Br J Psychiatry 1990; 156:798-808.
11. Amador XF, Strauss DH, Yale SA, Gorman JM. Awareness of illness in schizophrenia. Schizophr Bull 1991;17:113-132.
12. Cuesta MJ, Peralta V. Lack of insight in schizophrenia. Schizophr Bull 1994;20:359-366.
13. Lin IF, Spiga R, Fortsch W. Insight and adherence to medication in chronic schizophrenics. J Clin Psychiatry 1979;40: 430-432.
14. Marder SR, Mebane A, Ckien CP, Winslade WJ, Swann E, Van Putten T. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983;140:470-472.
15. Bartko G, Herczeg I, Zador G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988;77:74-76.
16. MacPherson R, Jerrom B, Hughes A. Relationship between insight, educational background and cognition in schizophrenia. Br J Psychiatry 1996;168:718-722.
17. McEvoy JP, Freter S, Everett G, Geller JL, Appelbaum P, Apperson LJ, et al. Insight and clinical outcome in schizophrenic patients. J Nerv Ment Dis 1989;177:48-51.
18. Barnes TRE, McPhillips MA, Hillier R, Puri BK, Joyce E. Compliance with maintenance medication in first episode schizophrenia. Schizophr Res 1997;24:205.
19. Markova IS, Berrios GE. Insight in clinical psychiatry revisited. Compr Psychiatry 1995;36:367-376.
20. Birchwood M, Smith J, Drury V, Healy J, MacMillan F, Slade MA. A self-report Insight Scale for psychosis: Reliability, validity and sensitivity to change. Acta Psychiatr Scand 1994;89: 62-67.
21. Kemp R, David A. Psychosis: Insight and compliance. Curr Opin Psychiatry 1995;8:357-360.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed. 3. Rev. Washington, DC: American Psychiatric Association, 1987.
23. Davis JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 1976;33:858-860.
24. Kane JM. Drug therapy: Schizophrenia. N Engl J Med 1996;334:34-39.
25. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures. Psychol Med 1992;22:347-352.
26. Fleischhaker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: Influence of side-effects. Acta Psychiatr Scand 1994;89(Suppl 382):11-15.
27. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273-279.
28. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting compliance. Psychiatric Serv 1997;48:82-85.
29. Green JH. Frequent rehospitalization and noncompliance with treatment. Hosp Commun Psychiatry 1988;39:963-966.
30. Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifiable risk factors for rehospitalization: A case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995;152:1749-1756.
31. Pan PC, Tantam D. Clinical characteristics, health beliefs and compliance with maintenance treatment: A comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 1989;79:564-570.
32. Van Putten T, May PRA, Marder SR, Wittman LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-190.
33. Barnes TRE, Kane JM. Choosing between old and new antipsychotics. Curr Opin Psychiatry 1996;9:41-44.
34. Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand 1994;89(Suppl 89):28-32.
35. Johnson DAW. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med 1977;17:564-569.
36. Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: The seven year follow-up of the Medical Research Council fluphenazine/placebo trial. Br J Psychiatry 1985;146:464-480.
37. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978;8:59-70.